{"url_path":"/sec/oric/8-k/2026-06-22/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1796280/0001193125-26-277511-index.html","accession_number":"0001193125-26-277511","cik":"0001796280","ticker":"ORIC","issuer_name":"Oric Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1796280/0001193125-26-277511-index.html","primary_entity_key":"0001796280","primary_entity_name":"Oric Pharmaceuticals, Inc."},"word_count":332,"has_tables":true,"body_markdown":"Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.\n\nORIC Pharmaceuticals, Inc. (the “Company”) amended and restated its 2020 Equity Incentive Plan (the “A&R 2020 Equity Incentive Plan”), effective as of June 18, 2026 upon approval by the stockholders of the Company at the Annual Meeting (as defined below).\n\nThe amendments to the A&R 2020 Equity Incentive Plan included (1) amending the annual “evergreen” provision to remove the annual limit of 2,656,500 shares while reducing the annual increase from 5% to 4% of the Company’s outstanding shares of common stock, (2) providing that, subject to the adjustment provisions of the A&R 2020 Equity Incentive Plan, the maximum number of shares of common stock that can be issued pursuant to the exercise of incentive stock options under the plan is 10,000,000, subject to the plan’s share reserve, and (3) eliminating the ability of the administrator of the A&R 2020 Equity Incentive Plan to implement a program under which (x) outstanding awards may be surrendered or cancelled in exchange for awards of the same type, awards of a different type, and/or cash, (y) participants would have the opportunity to transfer any outstanding awards to a financial institution or other person or entity selected by the administrator, and/or (z) the exercise price of an outstanding award may be reduced.\n\nThe material terms of the A&R 2020 Equity Incentive Plan are described in “Proposal No. 3 - Approval of the ORIC Pharmaceuticals, Inc. 2020 Equity Incentive Plan, as Amended and Restated” in the Company’s definitive proxy statement on Schedule 14A filed with the United States Securities and Exchange Commission on April 28, 2026, which description is incorporated herein by reference.\n\nThe foregoing description of the A&R 2020 Equity Incentive Plan is qualified in its entirety by reference to the text of the A&R 2020 Equity Incentive Plan, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference."}